A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

医学 内科学 危险系数 不利影响 科克伦图书馆 随机对照试验 置信区间 荟萃分析 肺癌 肿瘤科 相对风险 放化疗 毒性 放射治疗
作者
Qian Wu,Yiting Xiong,Shujuan Zhang,Xinling Chen,Fengming Yi,Yiping Wei
出处
期刊:Frontiers in Oncology [Frontiers Media SA]
卷期号:9 被引量:10
标识
DOI:10.3389/fonc.2019.01460
摘要

Background: Currently, the accepted standard management of limited-stage small cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT), but the frequency of radiotherapy is controversial. Therefore, this meta-analysis, which compared the efficacy and toxicity between twice-daily (BID) and once-daily (OD) CCRT, was performed to help clinicians make better decisions. Methods: Relevant randomized controlled trials (RCTs) were collected by searching the PubMed, Ovid MEDLINE, Embase, ScienceDirect, Web of Science, the Cochrane Library, Scopus and Google Scholar databases to assess antitumor effects (overall survival, OS; progression-free survival, PFS; overall response rate, ORR) and toxicity (adverse effects, AEs). Results: We screened 1499 articles and included 5 RCTs including 1421 patients. We found that BID CCRT improved OS (hazard ratio, HR = 0.88, 95% confidence interval, CI 0.78-0.99, p = 0.03), the 1-year OS rate (OSR-1y, risk ratio, RR = 1.07, 95%CI 1.01-1.13, p = 0.03), and OSR-4y (RR = 1.22, 95%CI 1.03-1.43, p = 0.02), with better trends in OSR-2y, OSR-3y, and OSR-5y, compared to OD CCRT. In addition, BID CCRT had a higher complete response (CR, RR = 1.31, 95%CI 1.01-1.70, p = 0.04) than OD CCRT. PFS (HR = 0.92, 95%CI 0.79-1.07, p = 0.29), annual PFS rate, ORR (RR = 0.99, 95%CI 0.93-1.05, p = 0.72), and AEs for all grades (RR = 1.00, 95%CI 0.98-1.01, p = 0.57), and grades 3-5 (RR = 1.02, 95%CI 0.95-1.09, p = 0.60) were similar between the two arms. Conclusions: BID CCRT appears to be better than OD CCRT for limited-stage SCLC, with better antitumor effects (OS, OSR, and CR) and similar AEs. However, the high levels of AEs in both arms should be taken as a sign of caution. More large sample and high-quality RCTs need to be conducted to confirm our conclusions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
suhaixin完成签到,获得积分10
1秒前
2秒前
李科研发布了新的文献求助30
2秒前
慕青应助ZL采纳,获得10
3秒前
4秒前
幽默孤容发布了新的文献求助30
5秒前
7秒前
zhaowen发布了新的文献求助10
7秒前
lyy发布了新的文献求助10
7秒前
10秒前
10秒前
雯明明完成签到,获得积分10
11秒前
11秒前
ZL完成签到,获得积分20
11秒前
zhaowen完成签到,获得积分10
13秒前
情怀应助niuniu采纳,获得10
14秒前
刘才华发布了新的文献求助10
14秒前
甜甜玫瑰应助害怕的篮球采纳,获得10
14秒前
大宝君应助害怕的篮球采纳,获得10
14秒前
ZL发布了新的文献求助10
15秒前
小许发布了新的文献求助10
16秒前
甜甜玫瑰应助心随以动采纳,获得10
17秒前
鲤鱼梦柳发布了新的文献求助10
17秒前
树懒发布了新的文献求助10
17秒前
18秒前
努力成为大佬完成签到 ,获得积分10
20秒前
CodeCraft应助Lq采纳,获得10
20秒前
无花果应助小许采纳,获得10
21秒前
22秒前
22秒前
特仑苏完成签到 ,获得积分10
23秒前
幽默孤容发布了新的文献求助10
23秒前
乐乐应助刘才华采纳,获得10
23秒前
24秒前
平常无颜发布了新的文献求助10
24秒前
阔达的寒凝关注了科研通微信公众号
26秒前
BSDL发布了新的文献求助10
26秒前
28秒前
niuniu发布了新的文献求助10
28秒前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 500
少脉山油柑叶的化学成分研究 430
Revolutions 400
MUL.APIN: An Astronomical Compendium in Cuneiform 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2454787
求助须知:如何正确求助?哪些是违规求助? 2126407
关于积分的说明 5415971
捐赠科研通 1855020
什么是DOI,文献DOI怎么找? 922513
版权声明 562340
科研通“疑难数据库(出版商)”最低求助积分说明 493626